Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Clinical trial NCT04550260 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04550260
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-19
- Primary completion
- 2027-06-30
- Enrollment
- 640
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.